Pharmacotherapy in familial hypercholesterolemia - Current state and emerging paradigms.

Abstract

Familial hypercholesterolemia is a highly prevalent but underdiagnosed disease marked by increased risk of cardiovascular morbidity and mortality. Aggressive reduction of LDL-cholesterol is a hallmark of cardiovascular risk mitigation in familial hypercholesterolemia. More recently, we have witnessed an expanded repertoire of pharmacologic agents that directly target LDL-cholesterol and/or reduce heart disease burden. In this state-of-the-art review, we explore the development, clinical efficacy and limitations of existing and potential future therapeutics in familial hypercholesterolemia.

• Authors: Aneesh Kallapur, Tamer Sallam
• Journal: Trends in cardiovascular medicine (Trends Cardiovasc Med) Vol. 33 Issue 3 Pg. 170-179 (04 2023) ISSN: 1873-2615 [Electronic] United States
• PMID: 34968676 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
• Copyright: Copyright © 2021. Published by Elsevier Inc.

Chemical References

• Cholesterol, LDL
• Anticholesteremic Agents

Topics

• Humans
• Hyperlipoproteinemia Type II (diagnosis, drug therapy, genetics)
• Cholesterol, LDL
• Treatment Outcome
• Heart Diseases (chemically induced)
• Heart Disease Risk Factors
• Anticholesteremic Agents (adverse effects)